EQT Life Sciences — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.
Biotech
Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in
BoardMichel Detheux(Chairman)in
Co-investorsBioqube VenturesFund+JDRF T1D Fund
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.Kurma PartnersOctalfaSofinnova Partners+3 more
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsAtlas VentureB Capital GroupB4 CapitalMRL Ventures FundPivotal Life SciencesSofinnova Partners+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Visus Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.










.jpeg)